These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19598262)

  • 21. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer.
    Nakazato T; Kanuma T; Tamura T; Faried LS; Aoki H; Minegishi T
    Int J Gynecol Cancer; 2007; 17(2):426-32. PubMed ID: 17309563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niclosamide Analogs for Treatment of Ovarian Cancer.
    Walters Haygood CL; Arend RC; Gangrade A; Chettiar S; Regan N; Hassmann CJ; Li PK; Hidalgo B; Straughn JM; Buchsbaum DJ
    Int J Gynecol Cancer; 2015 Oct; 25(8):1377-85. PubMed ID: 26186072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
    Maeda O; Shibata K; Hosono S; Fujiwara S; Kajiyama H; Ino K; Nawa A; Tamakoshi K; Kikkawa F
    Int J Cancer; 2012 Jan; 130(1):113-21. PubMed ID: 21328338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
    Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
    Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
    Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
    Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
    Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
    Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
    Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuregulin expression, function, and signaling in human ovarian cancer cells.
    Gilmour LM; Macleod KG; McCaig A; Sewell JM; Gullick WJ; Smyth JF; Langdon SP
    Clin Cancer Res; 2002 Dec; 8(12):3933-42. PubMed ID: 12473609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
    Han G; Gilks CB; Leung S; Ewanowich CA; Irving JA; Longacre TA; Soslow RA
    Am J Surg Pathol; 2008 Jul; 32(7):955-64. PubMed ID: 18460981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer.
    Wei L; Xue T; Wang J; Chen B; Lei Y; Huang Y; Wang H; Xin X
    Int J Cancer; 2009 Aug; 125(4):791-806. PubMed ID: 19391138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on the relationship between altered expression of annexin A4 and endometrial receptivity during the implantation window in infertile patients with endometriosis].
    Jiang YL; Li B; Xing FQ; Wang F; Feng JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):324-7. PubMed ID: 22883517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
    Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
    Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
    Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
    Yan XD; Pan LY
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.